Lymphoproliferative Disorder Clinical Trials

6 recruiting

Lymphoproliferative Disorder Trials at a Glance

30 actively recruiting trials for lymphoproliferative disorder are listed on ClinicalTrialsFinder across 6 cities in 13 countries. The largest study group is Phase 2 with 17 trials, with the heaviest enrollment activity in Columbus, Boston, and Bethesda. Lead sponsors running lymphoproliferative disorder studies include National Cancer Institute (NCI), Daihong Liu, and Cancer Research UK.

Browse lymphoproliferative disorder trials by phase

Treatments under study

About Lymphoproliferative Disorder Clinical Trials

Looking for clinical trials for Lymphoproliferative Disorder? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Lymphoproliferative Disorder trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Lymphoproliferative Disorder clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 30 trials

Recruiting

Study of Autoimmune Lymphoproliferative Syndrome (ALPS)

Benign Lymphoproliferative Disorder
National Institute of Allergy and Infectious Diseases (NIAID)1,200 enrolled1 locationNCT00001350
Recruiting
Phase 2

Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies

Lymphoproliferative DisordersImmune System DiseasesCommon Variable Immunodeficiency+2 more
National Cancer Institute (NCI)354 enrolled2 locationsNCT02579967
Recruiting
Phase 2

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

LymphomaEpstein-Barr Virus InfectionsLymphoproliferative Disorder+1 more
National Cancer Institute (NCI)40 enrolled1 locationNCT03258567
Recruiting
Phase 2

Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

Lymphoproliferative DisordersImmune System DiseasesPeripheral T-cell Lymphomas
National Cancer Institute (NCI)330 enrolled2 locationsNCT03922724
Recruiting

Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies

Lymphoproliferative DisordersNon-Hodgkin's LymphomaHodgkin's Disease+1 more
Dana-Farber Cancer Institute1,500 enrolled1 locationNCT00131014
Recruiting
Phase 2

Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder

Monomorphic B-Cell Post-Transplant Lymphoproliferative DisorderPolymorphic Post-Transplant Lymphoproliferative Disorder
Timothy Voorhees28 enrolled4 locationsNCT05786040
Recruiting
Phase 2

Epcoritamab in Previously Treated WM

Waldenstrom MacroglobulinemiaB-Cell Lymphoproliferative Disorder
Gottfried von Keudell, MD PhD20 enrolled3 locationsNCT06510491
Recruiting
Phase 1Phase 2

EBV-AST Cell Injection for EBV-Associated Lymphoproliferative Disorders

Epstein-Barr Virus-Associated Lymphoproliferative DisordersEBV-Positive Lymphoma
Daihong Liu18 enrolled1 locationNCT07450391
Recruiting
Phase 1Phase 2

EBV-AST Cell Therapy for EBV-Related Diseases After Stem Cell Transplantation

Post-Transplant Lymphoproliferative DisorderEBV-DNA Viremia
Daihong Liu18 enrolled1 locationNCT07438067
Recruiting
Not Applicable

Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021)

Acute LeukemiaChronic LeukemiaLymphoproliferative Disorders+2 more
Azienda Ospedaliero-Universitaria di Parma250 enrolled1 locationNCT07445984
Recruiting

Project: Every Child for Younger Patients With Cancer

Malignant Solid NeoplasmNeuroendocrine NeoplasmCentral Nervous System Neoplasm+15 more
Children's Oncology Group75,000 enrolled278 locationsNCT02402244
Recruiting
Phase 3

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)Solid Organ Transplant ComplicationsLymphoproliferative Disorders+2 more
Pierre Fabre Medicament115 enrolled71 locationsNCT03394365
Recruiting
Phase 2

A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

LeiomyosarcomaSolid Organ Transplant ComplicationsLymphoproliferative Disorders+8 more
Pierre Fabre Medicament190 enrolled40 locationsNCT04554914
Recruiting
Phase 2

Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms

Lymphoproliferative DisordersT-Cell Neoplasm
University of Michigan Rogel Cancer Center100 enrolled6 locationsNCT04858256
Recruiting
Phase 1Phase 2

Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation

Post-Transplant Lymphoproliferative DisorderEpstein-Barr Virus Infection
Daihong Liu18 enrolled1 locationNCT07368634
Recruiting
Not Applicable

Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)

Multiple MyelomaLymphoproliferative Disorder
Mayo Clinic82 enrolled7 locationsNCT06630104
Recruiting
Phase 1

EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma

EBV-Related Hodgkin LymphomaEBV-Related Lymphoproliferative DisorderEBV Related Non-Hodgkin's Lymphoma
Baylor College of Medicine52 enrolled2 locationsNCT04664179
Recruiting
Phase 2

A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia

Lymphoplasmacytic LymphomaWaldenström MacroglobulinemiaB-Cell Lymphoproliferative Disorder+1 more
Shayna Sarosiek, MD30 enrolled1 locationNCT06986174
Recruiting
Phase 2Phase 3

DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers

CancerRenal Cell CarcinomaLymphoma+8 more
Cancer Research UK30 enrolled27 locationsNCT05770037
Recruiting
Phase 2Phase 3

DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.

MalignancyMelanomaCancer+8 more
Cancer Research UK30 enrolled27 locationsNCT05770544